CaridianBCT, Inc. Launches Mononuclear Cell Collection Protocol for Spectra Optia(R) Apheresis System in Canada
Published: Sep 01, 2011
LAKEWOOD, Colo.--(BUSINESS WIRE)--CaridianBCT, the leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries announced today that the Spectra Optia System Mononuclear Cell (MNC) Collection protocol is now licensed by Health Canada and available for use in Canada. The availability of the MNC protocol—in addition to the therapeutic plasma exchange (TPE) and red blood cell exchange (RBCX) protocols—on the Spectra Optia system brings the value of efficiency, purity and consistency to cell collections—benefitting patients, clinicians and laboratory processes. The newest protocol offers Canadian medical institutions high CD34+ collection efficiency, optimized procedure times and product purity. Operators are empowered with a reliable, flexible system that performs under a variety of operational and patient conditions.